Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Three covalent hybrid inhibitors of SARS-CoV-2 main protease (Mpro) have been designed and compared to Pfizer’s nirmatrelvir (PF-07321332), providing atomic and thermodynamic details of their binding to the enzyme, and antiviral potency.
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Nature Portfolio
2022-04-01
|
| Seria: | Nature Communications |
| Dostęp online: | https://doi.org/10.1038/s41467-022-29915-z |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|